TNFR2: Role in Cancer Immunology and Immunotherapy

References

• Burugu S, Dancsok AR, Nielsen TO. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 2018;52(Pt 2):39–52.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723.
   PubMed Web of Science ®Google Scholar
• Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B. The TNF Paradox in Cancer progression and immunotherapy. Front Immunol. 2019;10:1818.
   PubMed Web of Science ®Google Scholar
• Montfort A, Dufau C, Colacios C, et al. Anti-TNF, a magic bullet in cancer immunotherapy? J Immunother Cancer. 2019;7(1):303.
   Web of Science ®Google Scholar
• Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin. 2008;29(11):1275–1288.
   PubMed Web of Science ®Google Scholar
• Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361–371. doi:10.1038/nrc2628
   PubMed Web of Science ®Google Scholar
• Murakami NBT, Yamashita M, Riella LV. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9(3):411–417.
   PubMed Web of Science ®Google Scholar
• ST TJ K, Trinh VA, Suarez-Almazor M, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76(12):2061–2064.
   Web of Science ®Google Scholar
• Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1):45–65.
   PubMed Web of Science ®Google Scholar
• Wajant H, Scheurich P. TNFR1‐induced activation of the classical NF‐κB pathway. FEBS J. 2011;278(6):862–876.
   Web of Science ®Google Scholar
• Xie P. TRAF molecules in cell signaling and in human diseases. J Mol Signal. 2013;8(1):7.
   PubMedGoogle Scholar
• Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell. 1993;74(5):845–853.
   PubMed Web of Science ®Google Scholar
• Heinrich M, Burger D, Wang L, et al. TNFR1 and TNFR2 Expression and induction on human treg cells from Type 1 diabetic subjects. Antibodies. 2015;4(1):34–47.
   Google Scholar
• Polz J, Remke A, Weber S, et al. Myeloid suppressor cells require membrane TNFR2 expression for suppressive activity. Immun Inflamm Dis. 2014;2(2):121–130.
   Google Scholar
• Shamdani S, Uzan G, Naserian S. TNFα-TNFR2 signaling pathway in control of the neural stem/progenitor cell immunosuppressive effect: different experimental approaches to assess this hypothetical mechanism behind their immunological function. Stem Cell Res Ther. 2020;11(1):307.
   Web of Science ®Google Scholar
• Dopp JM, Sarafian TA, Spinella FM, Kahn MA, Shau H, De Vellis J. Expression of the p75 TNF receptor is linked to TNF-induced NFκB translocation and oxyradical neutralization in glial cells. Neurochem Res. 2002;27(11):1535–1542.
   Web of Science ®Google Scholar
• Ware CF, Crowe PD, Vanarsdale TL, et al. Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells. J Immunol. 1991;147(12):4229–4238.
   Web of Science ®Google Scholar
• Chen X, Bäumel M, Männel DN, Howard OMZ, Oppenheim JJ. Interaction of TNF with TNF Receptor Type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol. 2007;179(1):154–161.
   PubMed Web of Science ®Google Scholar
• Chen X, Wu X, Zhou Q, Howard OMZ, Netea MG, Oppenheim JJ. TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J Immunol. 2013;190(3):1076–1084.
   Web of Science ®Google Scholar
• Govindaraj C, Scalzo-Inguanti K, Madondo M, et al. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clin Immunol. 2013;149(1):97–110.
   PubMed Web of Science ®Google Scholar
• Chen X, Subleski JJ, Kopf H, Howard OMZ, Männel DN, Oppenheim JJ. Cutting Edge: expression of TNFR2 Defines a Maximally Suppressive Subset of Mouse CD4+CD25+FoxP3+ T Regulatory Cells: applicability to Tumor-Infiltrating T Regulatory Cells. J Immunol. 2008;180(10):6467–6471.
   PubMed Web of Science ®Google Scholar
• Chen X, Hamano R, Subleski JJ, Hurwitz AA, Howard OM, Oppenheim JJ. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. J Immunol. 2010;185(1):174–182.
   PubMed Web of Science ®Google Scholar
• Yan F, Du R, Wei F, et al. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients. Cancer Immunol Immunother. 2015;64(11):1475–1485.
   Web of Science ®Google Scholar
• Chen X, Oppenheim JJ. Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer. Sci Sig. 2017;10:462.
   Web of Science ®Google Scholar
• Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol. 2000;18(1):423–449.
   Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–562.
   PubMed Web of Science ®Google Scholar
• Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–564.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T Cells and Immune Tolerance. Cell. 2008;133(5):775–787.
   PubMed Web of Science ®Google Scholar
• Panduro M, Benoist C, Mathis D. Tissue Tregs. Annu Rev Immunol. 2016;34(1):609–633.
   PubMed Web of Science ®Google Scholar
• Plitas G, Rudensky AY. Regulatory T cells in cancer. Annu Rev Cancer Biol. 2020;4(1):459–477.
   Google Scholar
• Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T cells and human disease. Annu Rev Immunol. 2020;38(1):541–566.
   PubMed Web of Science ®Google Scholar
• Taams LS, Palmer DB, Akbar AN, Robinson DS, Brown Z, Hawrylowicz CM. Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology. 2006;118(1):1–9.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of Regulatory T Cell development by the transcription Factor Foxp3. Science. 2003;299(5609):1057–1061.
   PubMed Web of Science ®Google Scholar
• Hill JA, Feuerer M, Tash K, et al. Foxp3 Transcription-factor-dependent and -independent regulation of the regulatory T Cell transcriptional signature. Immunity. 2007;27(5):786–800.
   PubMed Web of Science ®Google Scholar
• Azizi E, Carr AJ, Plitas G, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174(5):1293–1308.e1236.
   PubMed Web of Science ®Google Scholar
• De Simone M, Arrigoni A, Rossetti G, et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity. 2016;45(5):1135–1147.
   PubMed Web of Science ®Google Scholar
• Plitas G, Konopacki C, Wu K, et al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity. 2016;45(5):1122–1134.
   PubMed Web of Science ®Google Scholar
• Hamano R, Huang J, Yoshimura T, Oppenheim JJ, Chen X. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol. 2011;41(7):2010–2020.
   Web of Science ®Google Scholar
• Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83(5):793–802.
   PubMed Web of Science ®Google Scholar
• Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A. 1998;95(2):570–575.
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Cotton A, Attipoe L, Ciurtin C, Doré CJ, Ehrenstein MR. Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis. J Allergy Clin Immunol. 2018;142(3):978–980.e979.
   Web of Science ®Google Scholar
• Nguyen DX, Ehrenstein MR. Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF–TNF-RII binding in rheumatoid arthritis. J Exp Med. 2016;213(7):1241–1253.
   PubMed Web of Science ®Google Scholar
• Chen X, Oppenheim JJ. Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity. Nat Rev Rheumatol. 2016;12(11):625–626.
   Web of Science ®Google Scholar
• Kleijwegt FS, Laban S, Duinkerken G, et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol. 2010;185(3):1412–1418.
   Web of Science ®Google Scholar
• Chen X, Oppenheim JJ. Tetrandrine (TET), an immunosuppressive component of Chinese herb, induces tolerogenic dendritic cells and consequently expands regulatory T cells. J Immunol. 2016;196(1Supplement):70.78.
   Google Scholar
• He T, Yang D, Chen X, Oppenheim JJ. Tetrandrine (TET) up-regulated mTNF expression on dendritic cells and consequently induces TNFR2 mediated proliferation of Tregs. J Immunol. 2018;200(1Supplement):47.19.
   Google Scholar
• He T, Yang D, Li X-Q, et al. Inhibition of two-pore channels in antigen-presenting cells promotes the expansion of TNFR2-expressing CD4+Foxp3+ regulatory T cells. Sci Adv. 2020;6(40):eaba6584.
   Web of Science ®Google Scholar
• Chen X, Subleski JJ, Hamano R, Howard OMZ, Wiltrout RH, Oppenheim JJ. Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur J Immunol. 2010;40(4):1099–1106.
   PubMed Web of Science ®Google Scholar
• Chen X, Willette‐Brown J, Wu X, et al. IKKα is required for the homeostasis of regulatory T cells and for the expansion of both regulatory and effector CD4 T cells. FASEB J. 2015;29(2):443–454.
   Web of Science ®Google Scholar
• Okubo Y, Mera T, Wang L, Faustman DL. Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci Rep. 2013;3:3153.
   PubMed Web of Science ®Google Scholar
• He X, Landman S, Bauland SC, van den Dolder J, Koenen HJ, Joosten I. A TNFR2-agonist facilitates high purity expansion of human low purity Treg cells. PLoS One. 2016;11(5):e0156311.
   PubMed Web of Science ®Google Scholar
• Torrey H, Kühtreiber WM, Okubo Y, et al. A novel TNFR2 agonist antibody expands highly potent regulatory T cells. Sci Sig. 2020;13:661.
   Web of Science ®Google Scholar
• Miller PG, Bonn MB, McKarns SC. Transmembrane TNF-TNFR2 Impairs Th17 differentiation by promoting Il2 expression. J Immunol. 2015;195(6):2633–2647.
   Web of Science ®Google Scholar
• Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science. 1995;269(5229):1424–1427.
   Web of Science ®Google Scholar
• Carpentier I, Coornaert B, Beyaert R. Function and regulation of tumor necrosis factor receptor type 2. Curr Med Chem. 2004;11(16):2205–2212.
   PubMed Web of Science ®Google Scholar
• Kim EY, Teh HS. Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J Immunol. 2004;173(7):4500–4509.
   PubMed Web of Science ®Google Scholar
• Chen X, Li P, Yang X, Miao X, Luo H. Tumor necrosis factor receptor II (TNFR2) promotes the growth of mouse CT26 colon cancer. J Immunol. 2018;200(1Supplement):178.177.
   Google Scholar
• So T, Croft M. Regulation of PI-3-Kinase and Akt Signaling in T Lymphocytes and Other Cells by TNFR Family Molecules. Front Immunol. 2013;4:139.
   PubMed Web of Science ®Google Scholar
• He T, Liu S, Chen S, et al. The p38 MAPK Inhibitor SB203580 Abrogates tumor necrosis factor-induced proliferative expansion of mouse CD4+Foxp3+ Regulatory T cells. Front Immunol. 2018;9:1556.
   Web of Science ®Google Scholar
• Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov. 2010;9(6):482–493.
   PubMed Web of Science ®Google Scholar
• Adler HS, Kubsch S, Graulich E, Ludwig S, Knop J, Steinbrink K. Activation of MAP kinase p38 is critical for the cell-cycle–controlled suppressor function of regulatory T cells. Blood. 2007;109(10):4351–4359.
   Web of Science ®Google Scholar
• Adler HS, Steinbrink K. MAP kinase p38 and its relation to T cell anergy and suppressor function of regulatory T cells. Cell Cycle. 2008;7(2):169–175.
   PubMed Web of Science ®Google Scholar
• Ohkusu‐Tsukada K, Toda M, Udono H, Kawakami Y, Takahashi K. Targeted inhibition of IL‐10‐secreting CD25− Treg via p38 MAPK suppression in cancer immunotherapy. Eur J Immunol. 2010;40(4):1011–1021.
   Web of Science ®Google Scholar
• Urbano PCM, Koenen HJPM, Joosten I, He X. An Autocrine TNFα–tumor necrosis factor receptor 2 loop promotes epigenetic effects inducing human treg stability in vitro. Front Immunol. 2018;9:573.
   Web of Science ®Google Scholar
• Basu S, Hubbard B, Shevach EM. Foxp3-mediated inhibition of Akt inhibits Glut1 (glucose transporter 1) expression in human T regulatory cells. J Leukoc Biol. 2015;97(2):279–283.
   Web of Science ®Google Scholar
• Menk AV, Scharping NE, Moreci RS, et al. Early TCR signaling induces rapid aerobic glycolysis enabling distinct acute T cell effector functions. Cell Rep. 2018;22(6):1509–1521.
   PubMed Web of Science ®Google Scholar
• Frauwirth KA, Riley JL, Harris MH, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16(6):769–777.
   PubMed Web of Science ®Google Scholar
• Michalek RD, Gerriets VA, Jacobs SR, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011;186(6):3299–3303.
   PubMed Web of Science ®Google Scholar
• Gerriets VA, Kishton RJ, Johnson MO, et al. Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression. Nat Immunol. 2016;17(12):1459–1466.
   PubMed Web of Science ®Google Scholar
• Howie D, Cobbold SP, Adams E, et al. Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight. 2017;2:3.
   Web of Science ®Google Scholar
• de Kivit S, Mensink M, Hoekstra AT, et al. Stable human regulatory T cells switch to glycolysis following TNF receptor 2 costimulation. Nat Metab. 2020;1–16.
   Google Scholar
• Mahmud SA, Manlove LS, Schmitz HM, et al. Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells. Nat Immunol. 2014;15(5):473–481.
   PubMed Web of Science ®Google Scholar
• Yang S, Xie C, Chen Y, et al. Differential roles of TNFα-TNFR1 and TNFα-TNFR2 in the differentiation and function of CD4+Foxp3+ induced Treg cells in vitro and in vivo periphery in autoimmune diseases. Cell Death Dis. 2019;10(1):27.
   Web of Science ®Google Scholar
• Housley WJ, Adams CO, Nichols FC, et al. Natural but not inducible regulatory T Cells Require TNF-α Signaling for In Vivo Function. J Immunol. 2011;186(12):6779–6787.
   Web of Science ®Google Scholar
• Zhang Q, Cui F, Fang L, Hong J, Zheng B, Zhang JZ. TNF-α impairs differentiation and function of TGF-β-induced Treg cells in autoimmune diseases through Akt and Smad3 signaling pathway. J Mol Cell Biol. 2012;5(2):85–98.
   Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61(12):4766–4772.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity. Expert Opin Ther Targets. 2018;22(4):353–363.
   PubMed Web of Science ®Google Scholar
• Vanamee ES, Faustman DL. TNFR2: a Novel Target for Cancer Immunotherapy. Trends Mol Med. 2017;23(11):1037–1046.
   Web of Science ®Google Scholar
• Cohen JL, Wood KJ. TNFR2: the new Treg switch? OncoImmunology. 2018;7(1):e1373236.
   PubMed Web of Science ®Google Scholar
• Case K, Tran L, Yang M, Zheng H, Kuhtreiber WM, Faustman DL. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models. J Leukoc Biol. 2020;107(6):981–991.
   Web of Science ®Google Scholar
• Torrey H, Khodadoust M, Tran L, et al. Targeted killing of TNFR2-expressing tumor cells and T regs by TNFR2 antagonistic antibodies in advanced Sézary syndrome. Leukemia. 2019;33(5):1206–1218.
   Web of Science ®Google Scholar
• Yang M, Tran L, Torrey H, et al. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity. J Leukoc Biol. 2020;107(6):971–980.
   Web of Science ®Google Scholar
• He J, Li R, Chen Y, Hu Y, Chen X. TNFR2-expressing CD4+ Foxp3+ regulatory T cells in cancer immunology and immunotherapy. Prog Mol Biol Transl Sci. 2019;164:101–117.
   Web of Science ®Google Scholar
• Nie Y, He J, Shirota H, et al. Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer. Sci Sig. 2018;11(511):eaan0790.
   Web of Science ®Google Scholar
• Zou H, Li R, Hu H, Hu Y, Chen X. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents. Front Immunol. 2018;9:594.
   PubMed Web of Science ®Google Scholar
• Chen X, Yang Y, Zhou Q, et al. Effective Chemoimmunotherapy with Anti-TGFβ Antibody and cyclophosphamide in a mouse model of Breast Cancer. PLoS One. 2014;9(1):e85398.
   Web of Science ®Google Scholar
• Chang L-Y, Lin Y-C, Chiang J-M, et al. Blockade of TNF-α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion. OncoImmunology. 2015;4(10):e1040215.
   PubMed Web of Science ®Google Scholar
• Ham B, Wang N, D’Costa Z, et al. TNF Receptor-2 Facilitates an immunosuppressive microenvironment in the liver to promote the colonization and growth of hepatic metastases. Cancer Res. 2015;75(24):5235–5247.
   PubMed Web of Science ®Google Scholar
• Chopra M, Riedel SS, Biehl M, et al. Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis. 2013;34(6):1296–1303.
   Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163(10):5211–5218.
   PubMed Web of Science ®Google Scholar
• Ungewickell A, Bhaduri A, Rios E, et al. Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015;47(9):1056–1060.
   PubMed Web of Science ®Google Scholar
• Kampan NC, Madondo MT, McNally OM, Stephens AN, Quinn MA, Plebanski M. Interleukin 6 present in inflammatory ascites from advanced epithelial ovarian cancer patients promotes tumor necrosis factor receptor 2-expressing regulatory T cells. Front Immunol. 2017;8:1482.
   PubMed Web of Science ®Google Scholar
• Williams GS, Mistry B, Guillard S, et al. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget. 2016;7(42):68278–68291.
   Google Scholar
• Zhang T, Jiao J, Jiao X, et al. Aberrant frequency of TNFR2(+) Treg and related cytokines in patients with CIN and cervical cancer. Oncotarget. 2017;9(4):5073–5083.
   Google Scholar
• Torrey H, Butterworth J, Mera T, et al. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Sig. 2017;10:462.
   Web of Science ®Google Scholar
• Ghods A, Ghaderi A, Shariat M, Talei A-R A-R, Mehdipour F. TNFR2 but not TNFR1 is the main TNFR expressed by B and T lymphocytes in breast cancer draining lymph nodes. Immunol Lett. 2019;209:36–44. doi:10.1016/j.imlet.2019.03.013
   Web of Science ®Google Scholar
• Niu L. Abstract 1603: TNFR2+ regulatory T cells are key players in immune escape in gastric tumor microenvironment. Cancer Res. 2020;80(16 Supplement):1603.
   Google Scholar
• Yang D, Li R, Wang H, et al. Clinical significance of tumor necrosis factor receptor 2 in middle and lower thoracic esophageal squamous cell carcinoma. Oncol Lett. 2018;16(3):2971–2978. doi:10.3892/ol.2018.8998
   Web of Science ®Google Scholar
• Zhang YW, Chen QQ, Cao J, et al. Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker. Thorac Cancer. 2019;10(3):437–444. doi:10.1111/1759-7714.12948
   Web of Science ®Google Scholar
• Zhao T, Li H, Liu Z. Tumor necrosis factor receptor 2 promotes growth of colorectal cancer via the PI3K/AKT signaling pathway. Oncol Lett. 2017;13(1):342–346. doi:10.3892/ol.2016.5403
   Web of Science ®Google Scholar
• Yang F, Zhao N, Wu N. TNFR2 promotes Adriamycin resistance in breast cancer cells by repairing DNA damage. Mol Med Rep. 2017;16(3):2962–2968. doi:10.3892/mmr.2017.6898
   Web of Science ®Google Scholar
• Mestiri S, Bouaouina N, Ahmed SB, Chouchane L. A functional polymorphism of the tumor necrosis factor receptor-II gene associated with the survival and relapse prediction of breast carcinoma. Cytokine. 2005;30(4):182–187. doi:10.1016/j.cyto.2005.01.007
   PubMed Web of Science ®Google Scholar
• He L, Bhat K, Duhacheck-Muggy S, et al. Tumor necrosis factor receptor signaling modulates carcinogenesis in a mouse model of breast cancer. Neoplasia. 2021;23(2):197–209. doi:10.1016/j.neo.2020.12.007
   Web of Science ®Google Scholar
• Nomelini RS, Borges Júnior LE, de Lima CA, et al. TNF-R2 in tumor microenvironment as prognostic factor in epithelial ovarian cancer. Clin Exp Med. 2018;18(4):547–554. doi:10.1007/s10238-018-0508-3
   Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174.
   PubMed Web of Science ®Google Scholar
• Jiang J, Wang Z, Li Z, et al. Early exposure of high-dose interleukin-4 to tumor stroma reverses myeloid cell-mediated T-cell suppression. Gene Ther. 2010;17(8):991–999.
   Web of Science ®Google Scholar
• Youn JI, Gabrilovich DI. The biology of myeloid‐derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010;40(11):2969–2975.
   PubMed Web of Science ®Google Scholar
• Ba H, Li B, Li X, et al. Transmembrane tumor necrosis factor-α promotes the recruitment of MDSCs to tumor tissue by upregulating CXCR4 expression via TNFR2. Int Immunopharmacol. 2017;44:143–152.
   PubMed Web of Science ®Google Scholar
• Hu X, Li B, Li X, et al. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. J Immunol. 2014;192(3):1320–1331.
   Web of Science ®Google Scholar
• Zhao X, Rong L, Zhao X, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest. 2012;122(11):4094–4104.
   PubMed Web of Science ®Google Scholar
• Chavez-Galan L, Vesin D, Uysal H, et al. Transmembrane tumor necrosis factor controls myeloid-derived suppressor cell activity via TNF receptor 2 and protects from excessive inflammation during BCG-induced pleurisy. Front Immunol. 2017;8:999.
   Web of Science ®Google Scholar
• Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M. Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity. 2013;38(3):541–554.
   PubMed Web of Science ®Google Scholar
• Han Z, Jing Y, Zhang S, Liu Y, Shi Y, Wei L. The role of immunosuppression of mesenchymal stem cells in tissue repair and tumor growth. Cell Biosci. 2012;2(1):8.
   Web of Science ®Google Scholar
• Trivanović D, Krstić J, Djordjević IO, et al. The roles of mesenchymal stromal/stem cells in tumor microenvironment associated with inflammation. Mediators Inflamm. 2016;2016.
   Web of Science ®Google Scholar
• Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12(5):383–396.
   PubMed Web of Science ®Google Scholar
• Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer–cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood. 2008;111(3):1327–1333.
   PubMed Web of Science ®Google Scholar
• Maccario R, Podestà M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005;90(4):516–525.
   PubMed Web of Science ®Google Scholar
• Djouad F, Fritz V, Apparailly F, et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor α in collagen‐induced arthritis. Arthritis Rheum. 2005;52(5):1595–1603.
   PubMed Web of Science ®Google Scholar
• Yan L, Zheng D, Xu R-H. Critical role of tumor necrosis factor signaling in mesenchymal stem cell-based therapy for autoimmune and inflammatory diseases. Front Immunol. 2018;9:1658.
   PubMed Web of Science ®Google Scholar
• Miettinen JA, Pietilä M, Salonen RJ, et al. Tumor necrosis factor alpha promotes the expression of immunosuppressive proteins and enhances the cell growth in a human bone marrow-derived stem cell culture. Exp Cell Res. 2011;317(6):791–801.
   Web of Science ®Google Scholar
• Beldi G, Khosravi M, Abdelgawad ME, et al. TNFα/TNFR2 signaling pathway: an active immune checkpoint for mesenchymal stem cell immunoregulatory function. Stem Cell Res Ther. 2020;11(1):1–15.
   Web of Science ®Google Scholar
• Naserian S, Shamdani S, Arouche N, Uzan G. Regulatory T cell induction by mesenchymal stem cells depends on the expression of TNFR2 by T cells. Stem Cell Res Ther. 2020;11(1):534.
   PubMed Web of Science ®Google Scholar
• Beldi G, Bahiraii S, Lezin C, et al. TNFR2 is a crucial hub controlling mesenchymal stem cell biological and functional properties. Front Cell Dev Biol. 2020;8:1408.
   Web of Science ®Google Scholar
• de la Puente P, Muz B, Azab F, Azab AK. Cell trafficking of endothelial progenitor Cells in tumor progression. Clin Cancer Res. 2013;19(13):3360–3368.
   PubMed Web of Science ®Google Scholar
• Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7(11):1194–1201.
   PubMed Web of Science ®Google Scholar
• Bertok S, Wilson MR, Dorr AD, et al. Characterization of TNF receptor subtype expression and signaling on pulmonary endothelial cells in mice. Am J Physiol Lung Cell Mol Physiol. 2011;300(5):L781–L789.
   Web of Science ®Google Scholar
• Brockhaus M, Schoenfeld H-J, Schlaeger E-J, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 1990;87(8):3127–3131.
   Web of Science ®Google Scholar
• Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol. 1997;17(7):4015–4023.
   PubMed Web of Science ®Google Scholar
• Goukassian DA, Qin G, Dolan C, et al. Tumor necrosis factor-alpha receptor p75 is required in ischemia-induced neovascularization. Circulation. 2007;115(6):752–762.
   Web of Science ®Google Scholar
• Luo Y, Xu Z, Wan T, et al. Endothelial-Specific Transgenesis of TNFR2 promotes adaptive arteriogenesis and angiogenesis. Arterioscler Thromb Vasc Biol. 2010;30(7):1307–1314.
   Web of Science ®Google Scholar
• Nouri Barkestani M, Shamdani S, Afshar Bakshloo M, et al. TNFα priming through its interaction with TNFR2 enhances endothelial progenitor cell immunosuppressive effect: new hope for their widespread clinical application. Cell Commun Signal. 2021;19(1):1.
   Web of Science ®Google Scholar
• Naserian S, Abdelgawad ME, Bakshloo MA, et al. The TNF/TNFR2 signaling pathway is a key regulatory factor in endothelial progenitor cell immunosuppressive effect. Cell Commun Signal. 2020;18(1):1–14.
   Web of Science ®Google Scholar
• Wu LQ, Zhang WJ, Niu JX, et al. Phenotypic and functional differences between human liver cancer endothelial cells and liver sinusoidal endothelial cells. J Vasc Res. 2008;45(1):78–86.
   Web of Science ®Google Scholar
• Cosmi L, Liotta F, Lazzeri E, et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood. 2003;102(12):4107–4114.
   Web of Science ®Google Scholar
• Chakraborty S, Panda AK, Bose S, et al. Transcriptional regulation of FOXP3 requires integrated activation of both promoter and CNS regions in tumor-induced CD8+ Treg cells. Sci Rep. 2017;7(1):1628.
   Web of Science ®Google Scholar
• Rifa’i M, Shi Z, Zhang S-Y, et al. CD8+ CD122+ regulatory T cells recognize activated T cells via conventional MHC class I–αβTCR interaction and become IL-10-producing active regulatory cells. Int Immunol. 2008;20(7):937–947.
   Web of Science ®Google Scholar
• Colovai AI, Liu Z, Ciubotariu R, Lederman S, Cortesini R, Suciu-Foca N. Induction of xenoreactive CD4+ T-cell anergy by suppressor CD8+CD28- T cells. Transplantation. 2000;69(7):1304–1310.
   Web of Science ®Google Scholar
• Lu L, Yu Y, Li G, et al. CD8+ CD103+ regulatory T cells in spontaneous tolerance of liver allografts. Int Immunopharmacol. 2009;9(5):546–548.
   Web of Science ®Google Scholar
• Ablamunits V, Bisikirska B, Herold KC. Acquisition of regulatory function by human CD8+ T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010;40(10):2891–2901.
   PubMed Web of Science ®Google Scholar
• Horwitz DA, Pan S, Ou JN, et al. Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo. Clinical Immunology (Orlando, Fla). 2013;149(3):450–463.
   Web of Science ®Google Scholar
• Filaci G, Fenoglio D, Fravega M, et al. CD8+ CD28− T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol. 2007;179(7):4323–4334.
   PubMed Web of Science ®Google Scholar
• Chen C, Chen D, Zhang Y, et al. Changes of CD4+ CD25+ FOXP3+ and CD8+ CD28− regulatory T cells in non-small cell lung cancer patients undergoing surgery. Int Immunopharmacol. 2014;18(2):255–261.
   PubMed Web of Science ®Google Scholar
• Wu M, Chen X, Lou J, et al. TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment. Oncotarget. 2016;7:28.
   Google Scholar
• Alvarez Arias DA, Kim H-J, Zhou P, et al. Disruption of CD8+ treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity. Cancer Immunol Res. 2014;2(3):207–216.
   Web of Science ®Google Scholar
• Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3(10):944–950.
   PubMed Web of Science ®Google Scholar
• Mangan NE, Fallon RE, Smith P, van Rooijen N, McKenzie AN, Fallon PG. Helminth infection protects mice from anaphylaxis via IL-10-producing B cells. J Immunol. 2004;173(10):6346–6356.
   Web of Science ®Google Scholar
• Rowe V, Banovic T, MacDonald KP, et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood. 2006;108(7):2485–2492.
   Web of Science ®Google Scholar
• Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 2002;16(2):219–230.
   PubMed Web of Science ®Google Scholar
• Ticha O, Moos L, Wajant H, Bekeredjian-Ding I. Expression of Tumor necrosis factor Receptor 2 Characterizes TLR9-Driven formation of interleukin-10-producing B cells. Front Immunol. 2017;8:1951.
   PubMed Web of Science ®Google Scholar
• Schioppa T, Moore R, Thompson RG, et al. B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A. 2011;108(26):10662–10667.
   PubMed Web of Science ®Google Scholar
• Kim EY, Priatel JJ, Teh S-J, Teh H-S. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol. 2006;176(2):1026–1035.
   Web of Science ®Google Scholar
• Kim EY, Teh H-S. TNF type 2 receptor (p75) lowers the threshold of T cell activation. J Immunol. 2001;167(12):6812–6820.
   Web of Science ®Google Scholar
• Kim EY, Teh S-J, Yang J, Chow MT, Teh H-S. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth. J Immunol. 2009;183(10):6051–6057.
   Web of Science ®Google Scholar
• Calzascia T, Pellegrini M, Hall H, et al. TNF-α is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest. 2007;117(12):3833–3845.
   Web of Science ®Google Scholar
• Tam EM, Fulton RB, Sampson JF, et al. Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity. Sci Transl Med. 2019;11(512):eaax0720.
   Web of Science ®Google Scholar
• Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;377(6547):348–351.
   PubMed Web of Science ®Google Scholar
• Otano I, Alvarez M, Minute L, et al. Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death. Theranostics. 2020;10(10):4481–4489.
   Web of Science ®Google Scholar
• Wu S-Y, Fu T, Jiang Y-Z, Shao Z-M. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120.
   PubMed Web of Science ®Google Scholar
• Salagianni M, Baxevanis CN, Papamichail M, Perez SA. New insights into the role of NK cells in cancer immunotherapy. Oncoimmunology. 2012;1(2):205–207.
   PubMed Web of Science ®Google Scholar
• Mason AT, McVicar DW, Smith CA, Young HA, Ware CF, Ortaldo JR. Regulation of NK cells through the 80-kDa TNFR (CD120b). J Leukoc Biol. 1995;58(2):249–255.
   Web of Science ®Google Scholar
• Ivagnès A, Messaoudene M, Stoll G, et al. TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. Oncoimmunology. 2018;7(12):e1386826.
   PubMed Web of Science ®Google Scholar
• Xu J, Chakrabarti AK, Tan JL, Ge L, Gambotto A, Vujanovic NL. Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell–natural killer cell crosstalk. Blood. 2006;109(8):3333–3341.
   Web of Science ®Google Scholar
• Almishri W, Santodomingo-Garzon T, Le T, Stack D, Mody CH, Swain MG. TNFα augments cytokine-induced NK Cell IFNγ production through TNFR2. J Innate Immun. 2016;8(6):617–629.
   Web of Science ®Google Scholar
• Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015;27(1):55–62.
   PubMed Web of Science ®Google Scholar
• Lesage C, Longvert C, Prey S, et al. Incidence and clinical impact of Anti-TNFα treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the Mecolit survey. J Immunother. 2019;42(5):175–179.
   Web of Science ®Google Scholar
• Bertrand F, Montfort A, Marcheteau E, et al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017;8(1):1–13.
   Web of Science ®Google Scholar
• Bertrand F, Rochotte J, Colacios C, et al. Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–dependent immunity in experimental melanoma. Cancer Res. 2015;75(13):2619–2628.
   Web of Science ®Google Scholar
• Perez-Ruiz E, Minute L, Otano I, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019;569(7756):428–432.
   PubMed Web of Science ®Google Scholar
• Shortt J, Hsu AK, Johnstone RW. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene. 2013;32(36):4191–4202.
   Web of Science ®Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4(4):314–322.
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol. 1999;163(1):380–386.
   PubMed Web of Science ®Google Scholar
• Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363(9423):1802–1811.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Dmoszynska A, Kowal M, et al. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia. 2009;23(10):1771–1778.
   PubMed Web of Science ®Google Scholar
• Govindaraj C, Madondo M, Kong YY, Tan P, Wei A, Plebanski M. Lenalidomide‐based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. Am J Hematol. 2014;89(8):795–802.
   Web of Science ®Google Scholar
• Atretkhany K-SN, Mufazalov IA, Dunst J, et al. Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity. Proc Natl Acad Sci U S A. 2018;115(51):13051–13056.
   Web of Science ®Google Scholar
• Faustman DL. TNF inducers, and TNFR2 agonists: a new path to type 1 diabetes treatment. Diabetes Metab Res Rev. 2018;34(1):e2941.
   Web of Science ®Google Scholar
• Chopra M, Biehl M, Steinfatt T, et al. Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. J Exp Med. 2016;213(9):1881–1900.
   Web of Science ®Google Scholar
• Medler J, Wajant H. Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target. Expert Opin Ther Targets. 2019;23(4):295–307.
   PubMed Web of Science ®Google Scholar
• Fulton RB, Camblin A, Sampson JF, et al. Abstract 3270: mechanism of action of a novel agonist TNFR2 antibody that induces co-stimulation of T cells and promotes robust anti-tumor immunity. Cancer Res. 2019;79(13 Supplement):3270.
   Web of Science ®Google Scholar
• Sampson JF, Fulton RB, Kurella VB, et al. A novel TNFR2 antibody induces T cell co-stimulation and promotes durable anti-tumor immunity. J Immunol. 2019;202(1 Supplement):195.111.
   Google Scholar
• Richards J, Wong C, Koshkaryev A, et al. Abstract 4846: MM-401, a novel anti-TNFR2 antibody that induces T cell co-stimulation, robust anti-tumor activity and immune memory. Cancer Res. 2019;79(13 Supplement):4846.
   Web of Science ®Google Scholar
• Sampson JF, Kurella VB, Paragas V, et al. Abstract 555: a novel human TNFR2 antibody (MM-401) modulates T cell responses in anti-cancer immunity. Cancer Res. 2019;79(13 Supplement):555.
   Google Scholar
• Votavova P, Tomala J, Kovar M. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera. Immunol Lett. 2014;159(1–2):1–10.
   Web of Science ®Google Scholar
• Grell M, Becke FM, Wajant H, Männel DN, Scheurich P. Tumor necrosis factor (TNF) receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol. 1998;28(1):257–263.
   Web of Science ®Google Scholar
• Naudé PJW, den Boer JA, Luiten PGM, Eisel ULM. Tumor necrosis factor receptor cross-talk. The FEBS Journal. 2011;278(6):888–898.
   Web of Science ®Google Scholar
• Ban L, Zhang J, Wang L, Kuhtreiber W, Burger D, Faustman DL. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci U S A. 2008;105(36):13644–13649.
   Web of Science ®Google Scholar
• Okubo Y, Torrey H, Butterworth J, Zheng H, Faustman DL. Treg activation defect in type 1 diabetes: correction with TNFR2 agonism. Clin Transl Immunol. 2016;5(1):e56.
   Web of Science ®Google Scholar
• Lamontain V, Schmid T, Weber-Steffens D, et al. Stimulation of TNF receptor type 2 expands regulatory T cells and ameliorates established collagen-induced arthritis in mice. Cellular & Molecular Immunology. 2019;16(1):65–74.
   Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers. 2020;12(3):738.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–2532.
   PubMed Web of Science ®Google Scholar
• Khoja L, Atenafu EG, Ye Q, et al. Real‑world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncol Lett. 2016;11(2):1581–1585.
   PubMed Web of Science ®Google Scholar
• Hahn AW, Gill DM, Agarwal N, Maughan BL. PD-1 checkpoint inhibition: toxicities and management. Urol Oncol. 2017;35(12):701–707.
   Web of Science ®Google Scholar
• Migden MR, Rischin D, Schmults CD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018;379(4):341–351.
   PubMed Web of Science ®Google Scholar
• Govindaraj C, Tan P, Walker P, Wei A, Spencer A, Plebanski M. Reducing TNF Receptor 2+Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients. Clin Cancer Res. 2014;20(3):724–735.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247
   Google Scholar